CalciMedica, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
CalciMedica, Inc. (CALC) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $1.88 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-11
- CalciMedica, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.74, a 51.40% decline year-over-year.
- CalciMedica, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.58, a 95.33% decline year-over-year.
- CalciMedica, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $76.63.
- CalciMedica, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $2.16, a 97.13% decline from fiscal 2024.
- CalciMedica, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $75.27, a 6.75% increase from fiscal 2023.
- CalciMedica, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $70.51, a 1689.59% increase from fiscal 2022.
- CalciMedica, Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $3.94, a 68.53% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.88 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $1.74 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $2.16 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $3.36 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $3.71 10-Q · filed 2025-08-12 | |||
| 2025-03-31 | $3.58 10-Q · filed 2025-05-14 | |||
| 2024-12-31 | $75.27 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $75.27 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $75.27 10-Q · filed 2024-08-12 | |||
| 2024-03-31 | $76.63 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $70.51 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $70.79 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $70.79 10-Q · filed 2023-08-11 | |||
| 2022-12-31 | $3.94 10-K · filed 2023-03-09 | |||
| 2021-12-31 | $12.52 10-K · filed 2022-03-11 | |||
| 2020-12-31 | $2.38 10-K · filed 2021-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |